[{"Assets_0_Q3_USD":275837000.0,"CommonStockSharesOutstanding_0_Q3_shares":19090000.0,"EarningsPerShareBasic_1_Q3_USD":-0.44,"EarningsPerShareBasic_3_Q3_USD":-0.99,"EarningsPerShareDiluted_1_Q3_USD":-0.44,"EarningsPerShareDiluted_3_Q3_USD":-0.99,"NetIncomeLoss_1_Q3_USD":-8426000.0,"NetIncomeLoss_3_Q3_USD":-18798000.0,"StockholdersEquity_0_Q3_USD":260866000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":19081000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":19055000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":19081000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":19055000.0,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20170809"}]